Parallel Advisors’s Harmony Biosciences HRMY Stock Holding History

Parallel Advisors’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.31K	Buy	91 +10	+12%	+$315	﹤0.01%	3367
2026 Q1	$2.27K	Sell	81 -19	-19%	-$623	﹤0.01%	3327
2025 Q4	$3.74K	Buy	100 +7	+8%	+$230	﹤0.01%	2941
2025 Q3	$2.56K	Buy	93 +12	+15%	+$413	﹤0.01%	2989
2025 Q2	$2.56K	Sell	81 -8	-9%	-$257	﹤0.01%	2975
2025 Q1	$2.95K	Hold	89	–	–	﹤0.01%	2859
2024 Q4	$3.06K	Sell	89 -8	-8%	-$275	﹤0.01%	2822
2024 Q3	$3.88K	Buy	97 +7	+8%	+$246	﹤0.01%	2702
2024 Q2	$2.71K	Buy	90 +9	+11%	+$271	﹤0.01%	2716
2024 Q1	$2.72K	Hold	81	–	–	﹤0.01%	2727
2023 Q4	$2.62K	Buy	+81	New	+$2.26K	﹤0.01%	2721
2022 Q3	–	Sell	-7	Closed	–	–	3301
2022 Q2	$0	Buy	+7	New	+$315	﹤0.01%	3135
2021 Q4	–	Sell	-8	Closed	–	–	3168
2021 Q3	$0	Buy	+8	New	+$258	﹤0.01%	3147

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Capital Management Glen Allen, Virginia $666M AUM 17.17% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Universal-Beteiligungs- und Servicegesellschaft Frankfurt Am Main, Germany $65.4B AUM 39.83% 1-Year Est. Return

Parallel Advisors's HRMY Position: Q2 2026 in Review

Parallel Advisors increased its Harmony Biosciences (HRMY) stake by 12% in Q2 2026, buying an estimated $315 and bringing the position to 91 shares worth $3.31K. The position accounts for ﹤0.01% of the portfolio, ranked #3367.

Parallel Advisors first reported a position in HRMY in Q3 2021 and has held it in 13 quarters since. The position peaked at $3.88K in Q3 2024. 120 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

Parallel Advisors held 91 shares of Harmony Biosciences worth $3.31K as of Q2 2026.
Parallel Advisors bought 10 Harmony Biosciences shares in Q2 2026, an estimated $315.
Harmony Biosciences made up ﹤0.01% of Parallel Advisors's portfolio in Q2 2026, its #3367 holding.
Parallel Advisors first reported a position in Harmony Biosciences in Q3 2021 and has held it in 13 quarters since.
Parallel Advisors's Harmony Biosciences position peaked at $3.88K in Q3 2024.
120 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.